Stock Code:300238Mailbox Login




·In 31 May 2019, Benvitimod  (Commodity Name: Symbiox® ) was approved by Center for Drug Evaluation as State CategoryⅠNew Drug for the treatment of mild to moderate Psoriasis vulgaris.

·In July 2019, Ministry of Science and Technology published an article “Benvitimod, the worldwide innovative psoriasis drug, was approved by CDE” on its website.

·In October 2019, launch ceremony of Benvitimod named “Innovation of China leading the world” was held in the Great Hall of the People in Beijing.

·State CategoryⅠNew Drug、National Science and Technology Major Project、”Significant New Drugs Development”、obtained Intellectual Property Protection in China.

·Delay relapse: After 12 weeks of treatment, patients in the benvitimod group achieved a median remission period of 36 weeks.

·Better efficacy: 50 % of patients achieved PASI 75 at week 12 in the benvitimod group, which was significantly higher than that in either the calcipotriol group.

·Higher safety: Almost no systemic adverse drug reactions were found.

·Tripartite effects: Benvitimod can target to AhR, and prevent psoriasis recurrence.